Intro

This chapter highlights important discussions from Day 3 of the ACR Convergence 2024, emphasizing new recommendations for lupus nephritis treatment. It also examines a significant study on immune checkpoint inhibitors, revealing nuanced findings on their use in patients with autoimmune diseases.